Table 2. Outcomes of Treatment With Tucatinib Combined With Trastuzumab and Capecitabine (TTC).

	No. of patients	PFS		OS		TTNT, median (95% CI), mo
		Median (95% CI), mo	6-mo rate (95% CI)	Median (95% CI), mo	6-mo rate (95% CI)
Whole population	101	4.7 (3.9-5.6)	33.1 (24.8-44.3)	13.4 (11.1-NR)	77.0 (69.0-86.0)	5.2 (4.5-7.0)
Reason for trastuzumab-deruxtecan discontinuation
Toxic effects	18	7.3 (3.0-NR)	61.1 (42.3-88.3)	NR	81.7 (64.9-100.0)	7.8 (3.1-NR)
Progression	82	4.4 (3.9-5.5)	28.4 (19.9-40.6)	12.9 (11.1-NR)	75.7 (66.8-85.9)	5.2 (4.5-6.3)
Duration of previous trastuzumab-deruxtecan treatment in patients stopping for progression, mo
<6	23	4.7 (3.2-5.7)	17.4 (7.1-42.4)	10.6 (5.5-NR)	59.8 (42.6-84.1)	5.5 (4.8-NR)
≥6 to ≤12	36	3.9 (2.9-6.0)	23.1 (12.2-43.9)	NR	82.1 (70.1-96.2)	4.0 (3.5-6.1)
>12	23	5.6 (4.4-NR)	47.8 (31.2-73.3)	NR	81.7 (66.9-99.7)	7.2 (5.2-NR)
Line of treatment
Third to fourth	37	4.4 (3.4-8.0)	33.8 (21.0-54.2)	12.9 (10.2-NR)	79.6 (67.2-94.3)	4.8 (3.9-9.9)
Fifth or greater	64	4.7 (3.7-5.7)	32.8 (22.8-47.3)	13.4 (10.7-NR)	75.3 (65.2-87.1)	5.3 (4.7-7.0)
TTC immediately after trastuzumab-deruxtecan treatment
Yes	86	5.0 (4.2-6.0)	36.1 (26.9-48.4)	13.4 (11.9-NR)	78.0 (69.5-87.6)	5.5 (4.8-7.2)
No	15	3.5 (2.8-NR)	16.7 (5.0-56.1)	11.1 (8.3-NR)	72.0 (51.9-99.8)	3.8 (2.8-NR)
Population with brain metastases
Yes	39	5.0 (3.9-6.8)	32.4 (20.4-51.3)	12.9 (9.6-NR)	76.0 (63.4-91.1)	5.7 (4.7-8.6)
No	62	4.4 (3.5-6.0)	33.6 (23.2-48.8)	19.9 (10.7-NR)	77.7 (67.7-89.2)	4.8 (3.9-6.3)
Type
Active	16	4.7 (3.0-7.3)	25.0 (10.7-58.4)	12.4 (8.3-NR)	81.2 (64.2-100.0)	5.6 (4.4-NR)
Nonactive	23	5.2 (3.4-8.0)	37.9 (22.3-64.7)	17.0 (13.4-NR)	72.4 (55.7-94.2)	5.7 (4.7-NR)

Abbreviations: NR, not reached; OS, overall survival; PFS, progression-free survival; TTNT, time to next treatment.